NexMed Confirms Publication of New Femprox® Data in The Journal of Sexual Medicine

EAST WINDSOR, N.J.--(BUSINESS WIRE)--NexMed, Inc. (Nasdaq: NEXM), a developer of innovative products based on the NexACT^® drug delivery technology, today confirmed that previously unpublished clinical data on Femprox, the Company’s topical treatment for female sexual arousal disorder, was published in the August 2008 issue of The Journal of Sexual Medicine. The article, entitled, “Efficacy and Safety of Alprostadil Cream for the Treatment of Female Sexual Arousal Disorder: A Double-Blind, Placebo-Controlled Study in Chinese Population,” describes the results of NexMed’s 400 patient take-home study completed in China in 2005.

The Journal of Sexual Medicine is the official journal of the International Society for Sexual Medicine and the International Society for the Study of Women’s Sexual Health, and publishes original research in both basic science and clinical investigations for sexual medicine. A copy of the article is available by request to NexMed.

Second Quarter Conference Call

NexMed will file its 10-Q for the quarter ended June 30, 2008 on August 6, 2008. The Company’s 2008 second quarter conference call is scheduled for Thursday, August 7, 2008 at 10:00 a.m. EDT. At that time, management will review 2008 second quarter financial results, as well as the status of its products in the pipeline. The call can be accessed in the U.S. by dialing 877-407-9205 and outside of the U.S. by dialing 201-689-8054 and asking the conference operator for the NexMed Conference Call. The teleconference replay is available for one week by dialing in the U.S. 877-660-6853 and outside of the U.S. by dialing 201-612-7415. Replay pass codes 286 and 293079 are both required for playback. The conference call will also be Webcast live at URL http://www.investorcalendar.com/IC/CEPage.asp?ID=132842. The Webcast replay will be available for three months.

About NexMed

NexMed, Inc. is leveraging its proprietary NexACT drug delivery technology to develop innovative topical pharmaceutical products that address unmet medical needs. Novartis has completed pivotal Phase 3 trials for NexMed’s NM100060, a novel onychomycosis treatment exclusively licensed to Novartis. In November 2007, the Company signed a U.S. licensing agreement with Warner Chilcott for Vitaros®, NexMed’s erectile dysfunction product. NexMed's pipeline also includes Femprox, its Phase 2 treatment for female sexual arousal disorder, and an early stage treatment for psoriasis. For further information about NexMed, go to www.nexmed.com.

Statements under the Private Securities Litigation Reform Act: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described, including, but not limited to, obtaining regulatory approval for its products under development, entering into partnering agreements, pursuing growth opportunities, and/or other factors, some of which are outside the control of the Company.